Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Long-Term Morbidity and Mortality Experienced By Chronic Myeloid Leukemia (CML) Patients after Allogeneic Hematopoietic Cell Transplantation (HCT) - a Report from BMTSS-2

Jessica Wu, BA, Yanjun Chen, MS, Lindsey Hageman, MPH, Can-Lan Sun, PhD, Liton F. Francisco, BS, Emily C. Ness, BA, Mariel Parman, MPH, James A. Watson, MD, Daniel J. Weisdorf, MD, David S. Snyder, MD, Philip McGlave, MD, Stephen J. Forman, MD, Mukta Arora, MD, Saro Armenian, DO, MPH, Ravi Bhatia, MD, Smita Bhatia, MD MPH

Blood (2016) 128 (22): 823.

https://doi.org/10.1182/blood.V128.22.823.823

Published: 2016

Journal Articles

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

Veronika Bachanova, Sarah Cooley, Todd E. Defor, Michael R. Verneris, Bin Zhang, David H. McKenna, Julie Curtsinger, Angela Panoskaltsis-Mortari, Dixie Lewis, Keli Hippen, Philip McGlave, Daniel J. Weisdorf, Bruce R. Blazar, Jeffrey S. Miller

Blood (2014) 123 (25): 3855–3863.

https://doi.org/10.1182/blood-2013-10-532531

Published: 2014

Includes: Supplemental data

Journal Articles

IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,

Sarah Cooley, MD, Veronika Bachanova, Melissa Geller, MD, Michael R Verneris, MD, Bin Zhang, Valarie McCullar, David McKenna, MD, Dixie Lewis, Angela Panoskaltsis-Mortari, PhD, Daniel J. Weisdorf, MD, Philip McGlave, MD, Keli Hippen, Bruce R. Blazar, MD, Jeffrey S. Miller, MD

Blood (2011) 118 (21): 3611.

https://doi.org/10.1182/blood.V118.21.3611.3611

Published: 2011

Journal Articles

Blocking Inhibitory KIR Is Insufficient for Optimal Killing of AML and ALL Targets: Additional Requirements for NKG2A and LIR-1 Blockade

Robert Godal, Michelle Gleason, Valarie McCullar, Sarah Cooley, MD, Veronika Bachanova, Michael Verneris, MD, Philip McGlave, MD, Jeffrey S. Miller, MD

Blood (2008) 112 (11): 2906.

https://doi.org/10.1182/blood.V112.11.2906.2906

Published: 2008

Journal Articles

Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT)

Pamala A. Jacobson, Pharmd, Janel R Long, PharmD, John Rogosheske, PharmD, Kathleen Green, PharmD, Claudio Brunstein, MD, John E Wagner, MD, Qing Cao, MS, Jeffrey S. Miller, MD, Philip McGlave, MD, Daniel Weisdorf, MD

Blood (2008) 112 (11): 795.

https://doi.org/10.1182/blood.V112.11.795.795

Published: 2008

Journal Articles

High Resolution HLA Matched Unrelated Donor Versus HLA Identical Sibling Transplantation for Chronic Phase CML.

Mukta Arora, MD, MS, Stephen Spellman, MBS, Michael Haagenson, MS, John P. Klein, PhD, Carolyn Hurley, PhD, George Selby, MD, Joseph Antin, MD, Nancy Kernan, MD, Craig Kollman, PhD, Auayporn Nademanee, MD, Daniel J. Weisdorf, MD, Mary M. Horowitz, MD, MS, Philip McGlave, MD, Effie Petersdorf, MD

Blood (2007) 110 (11): 171.

https://doi.org/10.1182/blood.V110.11.171.171

Published: 2007

Journal Articles

Killer Immunoglobulin Receptor (KIR) Negative NK Cells Exhibit Potent Alloreactivity Against Primary Leukemia Targets When Interrupting MHC Class I Interactions through NKG2A Blockade.

Robert Godal, MD, Michelle Gleason, Valarie McCullar, Sarah Cooley, MD, Michael Verneris, MD, Philip McGlave, MD, Jeffrey S. Miller, MD

Blood (2007) 110 (11): 2862.

https://doi.org/10.1182/blood.V110.11.2862.2862

Published: 2007

Journal Articles

Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicty.

Pamala A. Jacobson, PharmD, John Rogosheske, PharmD, Kathleen Green, PharmD, Claudio Brunstein, MD, Juliet Barker, MD, Jeff Miller, MD, John Wagner, MD, Philip McGlave, MD, Ye Tan, MS, Daniel Weisdorf, MD

Blood (2005) 106 (11): 3673.

https://doi.org/10.1182/blood.V106.11.3673.3673

Published: 2005

Journal Articles

Oral Bioavailability of Mycophenolate Mofetil in Patients Undergoing Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Is Poor and Highly Variable.

Pamala Jacobson, PharmD, Green Kathleen, PharmD, John Rogosheske, PharmD, Claudio Brunstein, MD, Juliet Barker, MBBS, Todd DeFor, MS, Philip McGlave, MD, Daniel Weisdorf, MD

Blood (2005) 106 (11): 842.

https://doi.org/10.1182/blood.V106.11.842.842

Published: 2005

Journal Articles

NK Cell KIR Reconstitution after Allogeneic Hematopoietic Cell Transplant (HCT) Is Affected by T Cell Number and Function.

Sarah Cooley, Valarie McCullar, Rosanna Wangen, Tracy L. Bergemann, PhD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Philip McGlave, MD, Jeffrey S. Miller, MD

Blood (2005) 106 (11): 1406.

https://doi.org/10.1182/blood.V106.11.1406.1406

Published: 2005

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Acute Lymphocytic Leukemia (ALL) in 126 Adults: Impact of Donor Source on Leukemia Free Survival (LFS).

Priya Kumar, MD, Todd E. Defor, MS, Claudio Brunstein, MD, Juliet Barker, MBBS(Hons), John E. Wagner, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD, Philip McGlave, MD, Arne Slungaard, MD, Mukta Arora, MD, Marcie Tomblyn, MD, Linda J. Burns, MD

Blood (2005) 106 (11): 2064.

https://doi.org/10.1182/blood.V106.11.2064.2064

Published: 2005

Journal Articles

Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation

Daniel J. Weisdorf, Claudio Anasetti, Joseph H. Antin, Nancy A. Kernan, Craig Kollman, David Snyder, Effie Petersdorf, Gene Nelson, Philip McGlave

Blood (2002) 99 (6): 1971–1977.

https://doi.org/10.1182/blood.V99.6.1971

Published: 2002

Journal Articles

Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience

Effie W. Petersdorf, Craig Kollman, Carolyn Katovich Hurley, Bo Dupont, Auayporn Nademanee, Ann B. Begovich, Daniel Weisdorf, Philip McGlave

Blood (2001) 98 (10): 2922–2929.

https://doi.org/10.1182/blood.V98.10.2922

Published: 2001

NARROW

Long-Term Morbidity and Mortality Experienced By Chronic Myeloid Leukemia (CML) Patients after Allogeneic Hematopoietic Cell Transplantation (HCT) - a Report from BMTSS-2

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,

Blocking Inhibitory KIR Is Insufficient for Optimal Killing of AML and ALL Targets: Additional Requirements for NKG2A and LIR-1 Blockade

Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT)

High Resolution HLA Matched Unrelated Donor Versus HLA Identical Sibling Transplantation for Chronic Phase CML.

Killer Immunoglobulin Receptor (KIR) Negative NK Cells Exhibit Potent Alloreactivity Against Primary Leukemia Targets When Interrupting MHC Class I Interactions through NKG2A Blockade.

Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicty.

Oral Bioavailability of Mycophenolate Mofetil in Patients Undergoing Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Is Poor and Highly Variable.

NK Cell KIR Reconstitution after Allogeneic Hematopoietic Cell Transplant (HCT) Is Affected by T Cell Number and Function.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Acute Lymphocytic Leukemia (ALL) in 126 Adults: Impact of Donor Source on Leukemia Free Survival (LFS).

Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation

Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only